Lyse Santoro is an experienced leader in the pharmaceutical, diagnostics, and biotechnology industries, with over 25 years of expertise. An alumna of ENS, she holds an agrégation, a PhD, and a diploma from INSEAD. She has held strategic and operational positions in major international companies such as Transgène, bioMérieux, Pierre Fabre, and Ipsen, where she led an international business unit generating over €450 million in annual revenue.

Founder and President of DETERA Therapeutics, she combines a social mandate with an operational role. She previously served as an innovation advisor to Minister of Research Claudie Haigneré (2002-2004), contributing to key initiatives such as the Research Tax Credit (CIR), Young Innovative Company (JEI) status, and competitiveness clusters. Since 2021, she has been a Qualified Member of the Strategic Council for the Healthcare Industry (CSIS), playing a key role in the Health Innovation Plan presented by the President of France.

She has also held prominent leadership roles, notably as Leader of the G5 Group, Board Member of Medicen, and Member of HCERES, further strengthening her influence in the health and innovation sectors.

Her expertise spans executive leadership in companies of varying sizes under ISO13485 certification, strategic management, and fundraising (€30M+ raised from private funds, €10M+ in non-dilutive financing). She has overseen R&D programs, CE-certified product launches, clinical trials, and industrial partnerships across Europe and the United States.

Recognized for her contributions, Lyse Santoro was awarded the title of Chevalier of the Legion of Honor in 2023.

Back